Correspondence 0001193125-24-176818 from NewAmsterdam Pharma Co N.V. (NAMS, NAMSW) (CIK 0001936258) (NAMS)
NewAmsterdam Pharma Co N.V. (NAMS, NAMSW) (CIK 0001936258)
Date: July 9, 2024 · CIK: 0001936258 · Accession: 0001193125-24-176818
AI Filing Summary & Sentiment
File numbers found in text: 333-280687
Letter
NEWAMSTERDAM PHARMA COMPANY N.V.
Gooimeer 2-35
1411 DC Naarden
The Netherlands
July 9, 2024
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attn: Jason Drory
Re:
NewAmsterdam Pharma Company N.V.
Registration Statement on Form S-3
Filed July 3, 2024
File No. 333-280687
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), NewAmsterdam Pharma Company N.V. (the “Company”), hereby respectfully requests that the effective date of the above-referenced registration statement on Form S-3 (the “Registration Statement”) be accelerated by the Securities and Exchange Commission so that the Registration Statement will be declared effective under the Securities Act at 9:00 a.m. Eastern Time on July 12, 2024, or as soon thereafter as is practicable, or such other time as the Company or its counsel, Covington & Burling LLP, may request by telephone that such Registration Statement be declared effective.
We respectfully request that we be notified of such effectiveness by a telephone call to Brian K. Rosenzweig of Covington & Burling LLP at (212) 841-1108 and that such effectiveness also be confirmed in writing.
Very truly yours,
NEWAMSTERDAM PHARMA COMPANY N.V.
Show Raw Text
CORRESP 1 filename1.htm CORRESP NEWAMSTERDAM PHARMA COMPANY N.V. Gooimeer 2-35 1411 DC Naarden The Netherlands July 9, 2024 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Jason Drory Re: NewAmsterdam Pharma Company N.V. Registration Statement on Form S-3 Filed July 3, 2024 File No. 333-280687 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), NewAmsterdam Pharma Company N.V. (the “Company”), hereby respectfully requests that the effective date of the above-referenced registration statement on Form S-3 (the “Registration Statement”) be accelerated by the Securities and Exchange Commission so that the Registration Statement will be declared effective under the Securities Act at 9:00 a.m. Eastern Time on July 12, 2024, or as soon thereafter as is practicable, or such other time as the Company or its counsel, Covington & Burling LLP, may request by telephone that such Registration Statement be declared effective. We respectfully request that we be notified of such effectiveness by a telephone call to Brian K. Rosenzweig of Covington & Burling LLP at (212) 841-1108 and that such effectiveness also be confirmed in writing. Very truly yours, NEWAMSTERDAM PHARMA COMPANY N.V. By: /s/ Michael Davidson Name: Michael Davidson Title: Chief Executive Officer and Executive Director cc: Brian K. Rosenzweig, Covington & Burling LLP